Macrophage Reprogramming, Not CD8 T Cell Dynamics, Characterizes Durable Disease Control Following PD-1 Blockade in Smoldering Myeloma (IMS 2026) - Sep 11, 2026 - Abstract #PA-292; Pres time: Sep 24, 2026; P2 | "Here, we asked if and how myeloma patients respond to ICI using samples from a phase II trial of nivolumab (anti-PD-1) with lenalidomide and low-dose dexamethasone (NivoRd) in untreated high-risk smoldering multiple myeloma (HR-SMM) (NCT02903381). We find that depth of ICI response in HR-SMM is accompanied by treatment-associated macrophage inflammatory reprogramming coupled with a CD4+ T cell–macrophage signaling axis, rather than a canonical PD-L1 expression-dependent enhancement of CD8+ T-cell activity. This myeloid-centric mechanism provides a mechanistic framework for ICI efficacy in multiple myeloma and identifies potential biomarkers of response."
IO biomarker • Hematological Malignancies • Multiple Myeloma • Smoldering Multiple Myeloma • Solid Tumor • CD4 • CD8 • TNFA
|
|
Kane A. Foster1; Noe Perron1; Tarek H. Mouhieddine1; Robert A. Redd1; Sophie Magidson1; Jacqueline Perry1; Ashlee Sturtevant1; Christine Davie1; Caroline Ricciardi1; Frances Arters1; Marjorie Marto1; Amy Goguen1; Yuxin Liu1; Elizabeth O’Donnell1; Adam Sperling1; Jacob P. Laubach1; Paul G. Richardson1; Gad Getz2; Romanos Sklavenitis-Pistofidis1; Lorenzo Trippa1,3; Yoshinobu Konishi1; Omar Nadeem1; Irene Ghobrial1
|